Current Controversies, Recent Developments and Emerging Strategies in the Management of Breast Cancer: A Clinical Investigator Think TankRole, if any, of bevacizumab in breast cancer
1:14 minutes.
TRANSCRIPTION:
DR VOGEL: Basically, if you look at the two variables that the FDA made their decision on — efficacy and safety — I don’t think they really made their point well enough. In terms of safety, I think that there is no new safety signal in breast cancer that makes it any different than other tumor types where the drug is still available. In terms of efficacy, we really don’t have an appropriate marker. I think that, in the long run, it’s really going to be what happens to ECOG-E5103 in terms of overall survival. DR LOVE: That’s the adjuvant study. DR VOGEL: The adjuvant study. Because I think that if the adjuvant study turns out to be a positive study, then it would point in the direction that maybe FDA pulled the trigger a bit too quickly. I personally — bevacizumab was my go-to drug in really bad disease. |